Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.

被引：0
|
作者：
Morris, Michael J.
Solomon, Stephen Barnett
Durack, Jeremy C.
O'Donoghue, Joseph A.
Lyashchenko, Serge K.
Ruan Shutian
Carrasquillo, Jorge A.
Lewis, Jason Stuart
Martinez, Danny F.
Parada, Nicole A.
Keppler, Jennifer
Wu, Anna
Reuter, Victor E.
Weber, Wolfgang
Scher, Howard I.
Larson, Steven M.
Pandit-Taskar, Neeta
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Intervent Radiol & Image Guided Therapies, New York, NY 10021 USA
[3] ImaginAb Inc, Inglewood, CA USA
[4] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
    Schuchardt, Christiane
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Chen, Xiaoyuan
    Mueller, Dirk
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (08) : 1199 - 1207
  • [42] Safety profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status
    Gupta, M.
    Choudhury, P. S.
    Rawal, S.
    Goel, H. C.
    Talwar, V.
    Dutta, K. D.
    Singh, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
    Salgaller, ML
    Lodge, PA
    McLean, JG
    Tjoa, BA
    Loftus, DJ
    Ragde, H
    Kenny, GM
    Rogers, M
    Boynton, AL
    Murphy, GP
    PROSTATE, 1998, 35 (02): : 144 - 151
  • [44] Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, S. T.
    Parmar, S.
    Pena, J.
    Petrillo, K.
    Matulich, D.
    Selzer, J.
    Vallabhajosula, S.
    Goldsmith, S. J.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC)
    Khagi, Yulian
    Kaur, Gurveen
    Christos, Paul
    Akhtar, Naveed H.
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results
    Esen, Baris
    Seymen, Hulya
    Tarim, Kayhan
    Koseoglu, Ersin
    Bolukbasi, Yasemin
    Falay, Okan
    Selcukbiricik, Fatih
    Mandel, Nil Molinas
    Kordan, Yakup
    Demirkol, Mehmet Onur
    Tilki, Derya
    Esen, Tarik
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 832 - 837
  • [47] Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer A Phase 2 Clinical Trial
    Autio, Karen A.
    Dreicer, Robert
    Anderson, Justine
    Garcia, Jorge A.
    Alva, Ajjai
    Hart, Lowell L.
    Milowsky, Matthew I.
    Posadas, Edwin M.
    Ryan, Charles J.
    Graf, Ryon P.
    Dittamore, Ryan
    Schreiber, Nicole A.
    Summa, Jason M.
    Youssoufian, Hagop
    Morris, Michael J.
    Scher, Howard I.
    JAMA ONCOLOGY, 2018, 4 (10) : 1344 - 1351
  • [48] Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
    Murphy, GP
    Tjoa, BA
    Simmons, SJ
    Jarisch, J
    Bowes, VA
    Ragde, H
    Rogers, M
    Elgamal, A
    Kenny, GM
    Cobb, OE
    Ireton, RC
    Troychak, MJ
    Salgaller, ML
    Boynton, AL
    PROSTATE, 1999, 38 (01): : 73 - 78
  • [49] The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy
    Karimzadeh, Amir
    Heck, Matthias
    Tauber, Robert
    Solaris, Esteban
    Nekolla, Stephan
    Knorr, Karina
    Haller, Bernhard
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    Rauscher, Isabel
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1252 - 1258
  • [50] Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial
    Hamid, Anis
    Gupta, Santosh
    Keerthikumar, Shivakumar
    Pasam, Anupama
    Crumbaker, Megan
    Joshua, Anthony M.
    Lam, Ernest
    Wenstrup, Rick
    Emmett, Louise
    Goode, David L.
    Hofman, Michael S.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345